Zenas Biopharma Inc
ZBIO19.460USD
+0.395+2.07%
Close 09/18, 16:00（ET）Quotes delayed by 15 min
819.05MMarket Cap
LossP/E TTM
More Details of Zenas Biopharma Inc Company
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on the development and commercialization of immunology-based therapies for patients in need. Its lead immunology and inflammation (I&I) product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. It is developing obexelimab as a potential I&I franchise for patients in several autoimmune diseases. Its pipeline also includes two global programs, ZB002 (an anti-TNFα monoclonal antibody) and ZB004 (a CTLA-4-Ig fusion), and two regional programs, ZB001 (also known as VRDN-001, an IGF-1R monoclonal antibody), and related programs, and ZB005 (also known as DNTH103, an anti-active C1s monoclonal antibody), for which the Company hold the development and commercialization rights in greater China.
Company Info
Ticker SymbolZBIO
Company nameZenas Biopharma Inc
IPO dateSep 13, 2024
CEOMr. Leon O. Moulder, Jr.
Number of employees130
Security typeOrdinary Share
Fiscal year-endSep 13
Address1000 Winter St, Suite 1200
CityWALTHAM
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02451
Phone18572712954
Websitehttps://zenasbio.com/
Ticker SymbolZBIO
IPO dateSep 13, 2024
CEOMr. Leon O. Moulder, Jr.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Haley Laken, Ph.D.
Dr. Haley Laken, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Leon O. Moulder, Jr.
Mr. Leon O. Moulder, Jr.
Founder, Chairman of the Board of Director, Chief Executive Officer
Founder, Chairman of the Board of Director, Chief Executive Officer
--
--
Mr. Joseph L. (Joe) Farmer, J.D.
Mr. Joseph L. (Joe) Farmer, J.D.
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Patricia Allen
Ms. Patricia Allen
Independent Director
Independent Director
--
--
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
--
--
Mr. Patrick G. Enright
Mr. Patrick G. Enright
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Chief Business Officer, Chief Financial Officer
Chief Business Officer, Chief Financial Officer
--
--
Mr. James P. (Jim) Boylan
Mr. James P. (Jim) Boylan
Independent Director
Independent Director
--
--
Mr. Orlando Oliveira
Mr. Orlando Oliveira
Chief Commercial Officer
Chief Commercial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Haley Laken, Ph.D.
Dr. Haley Laken, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Leon O. Moulder, Jr.
Mr. Leon O. Moulder, Jr.
Founder, Chairman of the Board of Director, Chief Executive Officer
Founder, Chairman of the Board of Director, Chief Executive Officer
--
--
Mr. Joseph L. (Joe) Farmer, J.D.
Mr. Joseph L. (Joe) Farmer, J.D.
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Ms. Patricia Allen
Ms. Patricia Allen
Independent Director
Independent Director
--
--
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
--
--
Mr. Patrick G. Enright
Mr. Patrick G. Enright
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, May 16
Updated: Fri, May 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
SR One Capital Management, LP
11.66%
Enavate Sciences GP, LLC
8.93%
Xencor Inc
7.36%
Fidelity Management & Research Company LLC
7.34%
New Enterprise Associates (NEA)
6.49%
Other
58.21%
Shareholders
Shareholders
Proportion
SR One Capital Management, LP
11.66%
Enavate Sciences GP, LLC
8.93%
Xencor Inc
7.36%
Fidelity Management & Research Company LLC
7.34%
New Enterprise Associates (NEA)
6.49%
Other
58.21%
Shareholder Types
Shareholders
Proportion
Venture Capital
38.98%
Corporation
20.26%
Investment Advisor
14.70%
Investment Advisor/Hedge Fund
12.78%
Hedge Fund
11.25%
Individual Investor
0.80%
Research Firm
0.22%
Bank and Trust
0.05%
Pension Fund
0.02%
Other
0.94%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
129
40.20M
96.10%
+6.07M
2025Q1
127
41.72M
100.11%
+9.15M
2024Q4
102
40.82M
97.67%
+11.84M
2024Q3
52
37.70M
93.71%
+37.70M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SR One Capital Management, LP
4.91M
11.74%
--
--
Mar 31, 2025
Enavate Sciences GP, LLC
3.76M
8.99%
--
--
Mar 31, 2025
Xencor Inc
3.10M
7.41%
+3.10M
--
Sep 16, 2024
Fidelity Management & Research Company LLC
2.76M
6.59%
+977.45K
+54.87%
Mar 31, 2025
New Enterprise Associates (NEA)
2.61M
6.25%
--
--
Mar 31, 2025
Longitude Capital Management Co., LLC
2.50M
5.98%
+2.50M
--
Sep 16, 2024
Novo Holdings A/S
2.21M
5.29%
+614.97K
+38.44%
Mar 31, 2025
Fairmount Funds Management LLC
1.89M
4.52%
--
--
Apr 15, 2025
Federated Hermes Global Investment Management Corp.
1.16M
2.77%
--
--
Mar 31, 2025
Norwest Venture Partners
1.84M
4.39%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
